CN111718451A - 一种具有自修复性能的水凝胶材料及其制备方法和应用 - Google Patents
一种具有自修复性能的水凝胶材料及其制备方法和应用 Download PDFInfo
- Publication number
- CN111718451A CN111718451A CN202010587586.1A CN202010587586A CN111718451A CN 111718451 A CN111718451 A CN 111718451A CN 202010587586 A CN202010587586 A CN 202010587586A CN 111718451 A CN111718451 A CN 111718451A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- hydrogel material
- self
- repairing
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 90
- 239000000463 material Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 230000035876 healing Effects 0.000 claims abstract description 19
- 239000000178 monomer Substances 0.000 claims abstract description 15
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052709 silver Inorganic materials 0.000 claims abstract description 8
- 239000004332 silver Substances 0.000 claims abstract description 8
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000020638 mussel Nutrition 0.000 claims abstract description 7
- 239000002105 nanoparticle Substances 0.000 claims abstract description 7
- 238000004873 anchoring Methods 0.000 claims abstract description 6
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 6
- 239000003106 tissue adhesive Substances 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 58
- 206010052428 Wound Diseases 0.000 claims description 55
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- 229960003638 dopamine Drugs 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 229960003151 mercaptamine Drugs 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 230000003592 biomimetic effect Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- 239000000499 gel Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 8
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract description 5
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- 210000001126 granulation tissue Anatomy 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 206010057040 Temperature intolerance Diseases 0.000 abstract description 2
- 230000008543 heat sensitivity Effects 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003373 anti-fouling effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/34—Introducing sulfur atoms or sulfur-containing groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2353/00—Characterised by the use of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers
Abstract
本发明提供了一种具有自修复性能的水凝胶材料及其制备方法与应用,其是由聚乙二醇和N‑异丙基丙烯酰胺单体聚合而成的ABA型三嵌段网状共聚物,所述共聚物包含贻贝仿生组织粘合基团和银纳米颗粒锚定基团。本发明制备的水凝胶材料具有高度应变性、生物相容性、粘合性、热敏性、可注射性和抗微生物性等特性。在低温或是室温下可以实现有效的溶胶凝胶转变,同时该水凝胶具有良好的自修复性能,可以促进全层烧伤创面愈合速度,减少体内炎症因子释放、促进肉芽组织生长等作用。同时本发明提供的水凝胶材料能够根据临床需求搭载不同的药物。
Description
技术领域
本发明属于水凝胶材料技术领域,具体涉及一种具有自修复性能的水凝胶材料及其制备方法和应用。
背景技术
烧伤是一种由来源于包括热液、高温气体、火焰、炽热金属、化学物质等多种热力引起的组织损坏,主要发生于皮肤、粘膜等体表组织。机会出现严重的烧伤之后,除了区域性的皮肤粘膜局部损伤,还会产生以下反应:新陈代谢增加、体温下降、水分过度散失、蛋白质大量丢失以及内分泌和免疫系统的失调。其中暴露的烧伤创面,除了在短时间内会造成机体体液平衡紊乱、防御屏障的破坏之外,长期不愈合的创面还会成为细菌定植生长的温床。因此在烧伤发生后,尤其是大面积烧伤中,使用敷料覆盖创面,临时作为体表保护屏障,防止细菌的进一步入侵,促进创面愈合,就显得至关重要。
目前临床上针对烧伤创面大多使用的传统医用敷料,是以纱布、棉垫为主,其具有吸水性和一定的透气性,另外该传统医用敷料制作流程简单,价格便宜,可重复使用。但是传统敷料保湿效果不佳,且自身不具备抗菌能力,与此同时,还会出现敷料移位、脱落;更换伤口敷料时,因纱布干结、肉芽组织生长出现与创面的粘连,造成病人疼痛、出血等二次损伤。如何通过医用敷料促进深度的烧伤创面局部组织的再生和修复,逐渐引起临床医生的关注。已有研究得出,适宜的组织再生环境包括一定的湿度、温度和无菌条件。因此理想的敷料应具备吸收创面渗液、保持创面湿度温度、一定的透气性和抗菌能力等特点,从而促进创面愈合。
人们早就发现合成材料有助于促进皮肤创伤的愈合。1962年,伦敦大学的Winter博士在Nature杂志上发表著名论文,论证了湿润环境对创面的愈合作用:与用聚乙烯膜封闭猪断层皮肤缺损创面相比,暴露在空气中的创面再上皮化概率增加50%(Nature.1962;193:293-4)。Pulat等(Polymer edition.2013;24(7):807-819)以乙二醇二甲基丙烯酸酯为交联剂,以聚丙烯酰胺和壳聚糖为原料,合成了一种新型创面敷料──半渗透网络水凝胶,以期实现抗生素的突释和生长因子的控制释放。此凝胶的水含量非常高(约80%),并且在创面基质pH范围内(pH4.0-7.0)膨胀性质稳定;并且该种材料载有抗生素哌拉西林-三唑巴坦,生长因子为EGF;创面敷用此敷料1h,血清哌拉西林-三唑巴坦浓度即可达到治疗量,可实现EGF的持续释放达 5天的时间之久。Choi等(Journal ofbiomedical materialsresearch. 2010;95(2):564-573)制备了一种用于糖尿病性溃疡的创面黏附性感温水凝胶,将甲基丙烯酸缩水甘油酯化壳寡糖,二丙烯酰普朗尼克和 rhEGF共混制得物理交联水凝胶,再经光照射制得化学交联凝胶;小鼠背部烧伤创面敷用溶液状态的物理交联凝胶80μL(含1μg rhEGF),光照30s使其发生化学交联,再覆以医用绷带;研究结果表明,包封 rhEGF的水凝胶可提高创面的局部rhEGF浓度,维持角蛋白细胞的分化,从而促进难愈性创面的愈合。在上述一系列研究中,水凝胶是一种主要的有效成分。它作为一种高分子聚合物,性能优于传统敷料和生物敷料,其中的亲水集团使得水凝胶本身具体强大的吸水能力,吸水过后,水凝胶发生膨胀,与水分子牢固结合并保存,可以在吸收创面渗液的同时,具备一定保湿能力。水凝胶高分子交联形成的三维网状结构,使得其除了自身固有的特点之外,还可以成为某些特定药物的载体,发挥药物的功能。另一方面,多种研究表明,水凝胶的有机成分,具有改善创面微环境的能力,可以有效促进创面愈合。
然而水凝胶也存在很多不足。比如,水凝胶置于创面后,身体肌肉的运动易导致胶体的损坏甚至破裂,增加感染风险,同时也破坏水凝胶结构,影响其功能。除此之外,水凝胶本身也不具备抗菌性,无法抵御细菌的入侵,因此存在感染的风险。长期使用水凝胶之后,水凝胶因强大的吸水能力而发生肿胀,与创面贴合较差。另外,应用于烧伤创面的理想水凝胶剂需达到更高要求:自动修复敷料损坏,具备应变性;搭载部分药物,防止创面感染,具备抗菌性;状态可改变,具备长时间的贴合性;释放某种促进创面愈合的药物等;然而目前临床并没有能达到上述特性的水凝胶。
因此能否生产一种水凝胶敷料,在保证吸水性、保湿性的基础上,还可自动修复敷料损坏,具备应变性;搭载部分药物,防止创面感染,具备抗菌性;状态可改变,具备长时间的贴合性;同时,释放某种促进创面愈合的药物;这成为了一个值得研究的技术问题。另外,制备除具有以上性能的水凝胶敷料之外,能够制备出具有温敏性、自我修复能力、抗微生物性和防污染性的新型水凝胶敷料,成为本发明亟待解决的技术问题。
发明内容
本发明的目的就是为了解决上述技术问题,而提供一种具有自修复性能的水凝胶材料及其制备方法和应用。本发明提供的水凝胶材料可用于烧伤创面的快速愈合,其具有生物组织粘合性、温敏性和抗菌性,并能根据临床需求搭载不同的药物。
本发明的目的之一是提供一种具有自修复性能的水凝胶材料,所述水凝胶材料是由聚乙二醇单体和N-异丙基丙烯酰胺单体聚合而成的ABA型三嵌段网状共聚物,所述共聚物包含贻贝仿生组织粘合基团和银纳米颗粒锚定基团。
其中,所述贻贝仿生组织粘合基团为多巴胺基团,所述银纳米颗粒锚定基团为巯基。
本发明提供的上述水凝胶材料的结构具有如下特点:
1)本发明的水凝胶含有温敏响应基团,能够赋予水凝胶良好的温度响应性能,在常温或是低于体温条件下呈液体状态,在体温或是接触体表的时候转变为凝胶状态,方便于其储存运输,并且有益于手术使用如采用喷涂或注射使用;
2)贻贝仿生组织粘合基团(多巴胺基团),已经被证明可以赋予制备的粘合剂对生物组织良好的粘接性,该基团的引入可以保证水凝胶在使用过程中对烧伤组织良好的附着力;
3)银纳米颗粒锚定基团(巯基),该基团的引入可使水凝胶和银纳米颗粒之间进行有机的动态键结合,进一步提高银纳米颗粒复合水凝胶的强度。然后在低温条件下,将水凝胶与银纳米颗粒及CsA按照实验条件需求制备出具有合适浓度的水溶液,该溶液可以通过喷涂或注射使用与烧伤伤口处,通过伤口处的温度变化形成水凝胶保护层。
本发明提供的上述水凝胶的分子结构式如式(Ⅰ)所示:
其中,所述x、y、z均为1~n的整数。
上述水凝胶结构可以同时负载CsA和具有抗菌作用的银纳米颗粒,通过缓释让烧伤伤口始终处于抗菌及CsA给药的作用下。并且,由于该水凝胶存在儿茶酚氢键、pi-pi相互作用力及动态巯银键,因此该制备的复合水凝胶将具备良好的自修复性能,这一性能可以保证伤口在外力损坏进行自我修复免于因伤口的裸露带来的伤害。
本发明制备的水凝胶具有高度应变性、生物相容性、粘合性、热敏性、可注射性和抗微生物性等特性。该水凝胶在低温或是室温下可以实现有效的溶胶凝胶转变,该性能赋予这种材料良好的注射性和术后清理方便性,同时由于水凝胶中的主要成分为生物相容性良好的高分子材料如聚氧化乙烯(PEG),保证所得水凝胶材料对细胞有着优异的生物相容性。
本发明制备的水凝胶具有良好的自修复性能,对常见的E-coli 细菌具有优异的抗菌效果,同时对皮肤细胞明显防粘自清洁,同时该水凝胶的温度响应性使其使用方便,可以通过注射的方式进行。该水凝胶材料的力学强度可以通过改变贻贝仿生高分子材料中多巴胺的含量及其他组分的比例进行调节。
通过研究环孢素A在上述水凝胶敷料中对烧伤创面的促愈作用,提出CsA局部释放对于促进烧伤创面愈合以及减少烧伤局部炎症反应强度的作用。研究表明携带CsA的新型水凝胶敷料可以促进全层烧伤创面愈合速度,减少体内炎症因子释放、促进肉芽组织生长等作用。
本发明的目的之二是提供了上述具有自修复性能的水凝胶材料的制备方法,所述制备方法包括以下步骤:
(1)先将N-异丙基丙烯酰胺单体和聚乙二醇单体采用RAFT聚合法合成共聚物;
(2)然后将步骤(1)所得共聚物中的活性酯与多巴胺基团进行置换;
(3)向步骤(2)所得物中加入巯基乙胺进行化学接枝反应,得到所述水凝胶。
本发明的目的之三是提供上述水凝胶材料的应用,是将该水凝胶材料搭载药物后制成敷料,用于烧伤创面的快速愈合和修复。
与现有技术相比,本发明的有益效果如下:
本发明制备的水凝胶具有温敏性、自我修复能力、抗微生物性和防污染性,能够很好作为烧伤创面愈合用的敷料,该水凝胶可负载 CsA和具有抗菌作用的银纳米颗粒,通过缓释让烧伤伤口始终处于抗菌及CsA给药的作用下。能够具备良好的自修复性能,保证伤口在外力损坏进行自我修复免于因伤口的裸露带来的伤害。同时该水凝胶敷料可以促进全层烧伤创面愈合速度,减少体内炎症因子释放、促进肉芽组织生长等作用。
附图说明
图1为本发明的水凝胶结构示意图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例对本发明进行具体描述,有必要指出的是,以下实施例仅仅用于对本发明进行解释和说明,并不用于限定本发明。本领域技术人员根据上述发明内容所做出的一些非本质的改进和调整,仍属于本发明的保护范围。
实施例1
一种具有自修复性能的水凝胶材料,其结构式如下:
该水凝胶的制备方法参考“ACS applied materials&interfaces. 2017;9(11):9221-9225”中的方法,具体为:(1)先将N-异丙基丙烯酰胺单体和聚乙二醇单体采用RAFT聚合法合成共聚物;(2)然后将步骤(1)所得共聚物中的活性酯与多巴胺基团进行置换;(3)向步骤(2)所得物中加入巯基乙胺进行化学接枝反应,得到所述水凝胶。其中聚乙二醇的数均分子量为2000-6000,聚乙二醇单体与N-异丙基丙烯酰胺单体的质量比为1~2:2~1。
上述所得水凝胶的结构示意图如图1所示。
实验例1
构建大鼠重度烧伤模型,将实施例1所得水凝胶搭载CsA和银纳米颗粒,制备成水凝胶敷料,探讨实施例1所得水凝胶敷料对于烧伤后大鼠局部组织恢复的保护作用和全身炎症反应的抑制作用,其方法如下:
取40只大鼠,分为4组,对照组(Control)、模型组(Burn)、阳性对照组(Burn+Intrasite Gel)、实验组(Burn+HydrogelA)。全部大鼠于背部剃毛,用1%戊巴比妥钠1mL腹腔注射进行全麻,取面积为30%总体表面积(TBSA=K*W*0.5,K=0.9,W为小鼠体重)为烧伤面积。除对照组外全部大鼠麻醉后于99摄氏度的水中烫伤15秒,对照组大鼠麻醉后与37摄氏度的水中温浴15秒。
烧伤后1d处理创面。实验组,创面用搭载CsA的新型水凝胶敷料处理;阳性对照组,创面用清得佳(Intrasite Gel,一种临床常用水凝胶敷料)处理;模型组不给药,其余处理一致。在大鼠麻醉后,背部以洗必泰清洗消毒后,按照分组情况给药,给药厚度为3~5mm,防止药品脱落。在烧伤后3、7、10、14d,采用Image Pro Plus软件测量并记录创面愈合过程、计算痂面面积、创面愈合率、完全愈合时间,观察创面形态变化。
统计实验结果如表1所示:
表1
另外,在烧伤后3、7、10、14d,采用尾静脉采血,分别在各个时间点取4组大鼠血液,离心得血清,使用Varioskan Flash多功能酶标仪以及ELISA试剂盒,检测IL-6和TNF-α(肿瘤坏死因子-α)水平;采用rt-PCR方法检测血清中mtDNA含量。同时在烧伤后14天,取创面组织,分别检测创面肉芽组织之间结构组织变化,胶原的分布以及EFG-2的表达情况。
所得结果如表2和3所示:
表2
表3
上述实验结果表明,携带CsA的新型水凝胶敷料可以发挥促进全层烧伤创面的愈合,提高愈合速度,减少体内炎症因子释放、促进内皮细胞生长等作用。
实验例2
将“ACS applied materials&interfaces.2017;9(11):9221-9225”中制得的水凝胶用于上述大鼠重度烧伤模型,记为阳性对照组2,通过负载CsA,结果如表4:
表4
Claims (8)
1.一种具有自修复性能的水凝胶材料,其特征在于,所述水凝胶材料是由聚乙二醇单体和N-异丙基丙烯酰胺单体聚合而成的ABA型三嵌段网状共聚物,所述共聚物包含贻贝仿生组织粘合基团和银纳米颗粒锚定基团。
2.根据权利要求1所述的具有自修复性能的水凝胶材料,其特征在于,所述贻贝仿生组织粘合基团为多巴胺基团。
3.根据权利要求1所述的具有自修复性能的水凝胶材料,其特征在于,所述银纳米颗粒锚定基团为巯基。
4.根据权利要求1所述的具有自修复性能的水凝胶材料,其特征在于,所述聚乙二醇的分子量为2000-6000Da。
5.根据权利要求1所述的具有自修复性能的水凝胶材料,其特征在于,所述聚乙二醇单体与N-异丙基丙烯酰胺单体的质量比为1~2:2~1。
7.一种如权利要求1-6任一项所述具有自修复性能的水凝胶材料的制备方法,其特征在于,所述制备方法包括以下步骤:
(1)先将N-异丙基丙烯酰胺单体和聚乙二醇单体采用RAFT聚合法合成共聚物;
(2)然后将步骤(1)所得共聚物中的活性酯与多巴胺基团进行置换;
(3)向步骤(2)所得物中加入巯基乙胺进行化学接枝反应,得到所述水凝胶。
8.一种如权利要求1-6任一项所述具有自修复性能的水凝胶材料的应用,其特征在于,是将该水凝胶材料搭载环孢素A后制成敷料,用于烧伤创面的快速愈合和修复。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010587586.1A CN111718451A (zh) | 2020-06-24 | 2020-06-24 | 一种具有自修复性能的水凝胶材料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010587586.1A CN111718451A (zh) | 2020-06-24 | 2020-06-24 | 一种具有自修复性能的水凝胶材料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111718451A true CN111718451A (zh) | 2020-09-29 |
Family
ID=72568707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010587586.1A Pending CN111718451A (zh) | 2020-06-24 | 2020-06-24 | 一种具有自修复性能的水凝胶材料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111718451A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112168952A (zh) * | 2020-10-27 | 2021-01-05 | 成都市妇女儿童中心医院 | 水凝胶搭载环孢素a在制备治疗心肌缺血再灌注损伤的药物中的应用 |
CN113599571A (zh) * | 2021-07-26 | 2021-11-05 | 哈尔滨贝科德糖生物科技有限公司 | 一种可注射的羧甲基壳聚糖/壳寡糖自愈合水凝胶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170190844A1 (en) * | 2016-01-06 | 2017-07-06 | The Governors Of The University Of Alberta | Hydrogel |
CN107522875A (zh) * | 2016-06-20 | 2017-12-29 | 中国科学院宁波材料技术与工程研究所 | 银纳米粒子交联的水凝胶、其制备方法及应用 |
CN109646393A (zh) * | 2018-11-21 | 2019-04-19 | 惠众国际医疗器械(北京)有限公司 | 一种用于体表创面修复的温敏型凝胶及其制备方法 |
-
2020
- 2020-06-24 CN CN202010587586.1A patent/CN111718451A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170190844A1 (en) * | 2016-01-06 | 2017-07-06 | The Governors Of The University Of Alberta | Hydrogel |
CN107522875A (zh) * | 2016-06-20 | 2017-12-29 | 中国科学院宁波材料技术与工程研究所 | 银纳米粒子交联的水凝胶、其制备方法及应用 |
CN109646393A (zh) * | 2018-11-21 | 2019-04-19 | 惠众国际医疗器械(北京)有限公司 | 一种用于体表创面修复的温敏型凝胶及其制备方法 |
Non-Patent Citations (1)
Title |
---|
LIN LI,ET AL.: "Novel Mussel-Inspired Injectable Self-Healing Hydrogel with Anti-Biofouling Property", 《ADVANCED MATERIALS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112168952A (zh) * | 2020-10-27 | 2021-01-05 | 成都市妇女儿童中心医院 | 水凝胶搭载环孢素a在制备治疗心肌缺血再灌注损伤的药物中的应用 |
CN113599571A (zh) * | 2021-07-26 | 2021-11-05 | 哈尔滨贝科德糖生物科技有限公司 | 一种可注射的羧甲基壳聚糖/壳寡糖自愈合水凝胶及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xiang et al. | Status and future scope of hydrogels in wound healing: Synthesis, materials and evaluation | |
Zhang et al. | Alginate hydrogel dressings for advanced wound management | |
Gruppuso et al. | Polymeric wound dressings, an insight into polysaccharide-based electrospun membranes | |
Gupta et al. | The production and application of hydrogels for wound management: A review | |
Moura et al. | Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review | |
Rezvani Ghomi et al. | Wound dressings: Current advances and future directions | |
Kamoun et al. | A review on polymeric hydrogel membranes for wound dressing applications: PVA-based hydrogel dressings | |
US11471335B2 (en) | Gel-within-gel wound dressing | |
Torres et al. | Starch‐based biomaterials for wound‐dressing applications | |
Boateng et al. | Wound healing dressings and drug delivery systems: a review | |
Chopra et al. | Strategies and therapies for wound healing: a review | |
RU2422133C1 (ru) | Гидрофильный гель, способ его получения (варианты), раневое покрытие и перевязочное средство на его основе | |
CN111643720A (zh) | 一种具有抗菌性能的烧伤创面愈合用水凝胶及其制备方法 | |
US20060018955A1 (en) | Method for preparing medical dressings | |
Lee et al. | Wound healing evaluation of sodium fucidate-loaded polyvinylalcohol/sodium carboxymethylcellulose-based wound dressing | |
de Souza et al. | Biopolymer-based films and membranes as wound dressings | |
CN111718451A (zh) | 一种具有自修复性能的水凝胶材料及其制备方法和应用 | |
Liu et al. | A tunable multifunctional hydrogel with balanced adhesion, toughness and self-healing ability prepared by photopolymerization under green LED irradiation for wound dressing | |
CN112999412A (zh) | 用于伤口愈合的水凝胶敷料及其制备方法 | |
CN111073001A (zh) | 一种两性葡聚糖水凝胶及应用 | |
Chen et al. | The role of gel wound dressings loaded with stem cells in the treatment of diabetic foot ulcers | |
KR20120114031A (ko) | 히알루론산과 콘드로이틴 설페이트를 함유한 수화겔 및 이의 제조방법 | |
CN113144280A (zh) | 智能抗菌水凝胶及其应用 | |
Konur | The pioneering research on the wound care by alginates | |
Matthews | Drug delivery dressings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200929 |